Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: A practical guide

Maturitas

Volumn 80, Issue 4, 2015, Pages 435-440

  Palacios, Santiago ^a   Currie, Heather ^b   Mikkola, Tomi S ^c   Dragon, Erika ^d  

^a Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^b NHS DUMFRIES AND GALLOWAY   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d PFIZER INC   (United States)

Author keywords

Bazedoxifene; Hot flashes; Menopause; Osteoporosis; Postmenopausal hormone replacement therapy; Selective estrogen receptor modulators (SERMs)

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AMENORRHEA; BONE MASS; BREAST DENSITY; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN DEFICIENCY; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL VEIN THROMBOSIS; REVIEW; THROMBOPHLEBITIS; VENOUS THROMBOEMBOLISM; ADULT; BONE DENSITY; BREAST; CHEMICALLY INDUCED; DEFICIENCY; DRUG COMBINATION; DRUG EFFECTS; HOT FLASHES; MENOPAUSE; UTERUS BLEEDING;

ADULT; AMENORRHEA; BONE DENSITY; BREAST; DRUG THERAPY, COMBINATION; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE HEMORRHAGE; VENOUS THROMBOEMBOLISM;

EID: 84925258553     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.01.003     Document Type: Review

References (36)

1. European Medicines Agency Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women 2006 [cited 2014 May 19]. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003348.pdf
2. T.J. de Villiers, A. Pines, and N. Panay Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health Climacteric 16 2013 316 337
3. J.E. Manson, R.T. Chlebowski, and M.L. Stefanick Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials JAMA 310 2013 1353 1368
4. I. Persson, E. Thurfjell, and L. Holmberg Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density J Clin Oncol 15 1997 3201 3207
5. S. Kaewrudee, S. Anuwutnavin, J. Kanpittaya, S. Soontrapa, and C. Sakondhavat Effect of estrogen-progestin and estrogen on mammographic density J Reprod Med 52 2007 513 520
6. M. Hickey, D. Ameratunga, and J.L. Marino Unscheduled bleeding in continuous combined hormone therapy users Maturitas 70 2011 400 403
7. B.S. Komm, and S. Mirkin Evolution of the tissue selective estrogen complex (TSEC) J Cell Physiol 228 2013 1423 1427
8. B.S. Komm, Y.P. Kharode, P.V. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 146 2005 3999 4008
9. K.C. Chang, Y. Wang, P.V. Bodine, S. Nagpal, and B.S. Komm Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens J Steroid Biochem Mol Biol 118 2010 117 124
10. Y. Song, R.J. Santen, J.P. Wang, and W. Yue Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro Endocrinology 154 2013 656 665
11. S. Palacios, T.J. de Villiers, and F.C. Nardone Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study Maturitas 76 2013 81 87
12. European Medicines Agency Dauvive [summary of product characteristics] 2014 European Medicines Agency London, United Kingdom
13. Wyeth Pharmaceuticals Inc. Duavee [package insert] 2013 Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer Inc. Philadelphia, PA
14. J.H. Pickar, I.T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 92 2009 1018 1024
15. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 2009 1116 1124
16. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2010 281 289
17. S. Mirkin, B.S. Komm, K. Pan, and A.A. Chines Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric 16 2013 338 346
18. J.V. Pinkerton, J.A. Harvey, and R. Lindsay Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial J Clin Endocrinol Metab 99 2014 E189 E198
19. R.A. Lobo, J.V. Pinkerton, and M.L. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertil Steril 92 2009 1025 1038
20. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 2009 1045 1052
21. J.V. Pinkerton, K. Pan, and L. Abraham Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial Menopause 21 2014 252 259
22. P.A. Carney, D.L. Miglioretti, and B.C. Yankaskas Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography Ann Intern Med 138 2003 168 175
23. J.V. Pinkerton, J.A. Harvey, and K. Pan Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial Obstet Gynecol 121 2013 959 968
24. J.A. Harvey, J.V. Pinkerton, E.C. Baracat, H. Shi, A.A. Chines, and S. Mirkin Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens Menopause 20 2013 138 145
25. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 2009 1039 1044
26. T.J. de Villiers, A.A. Chines, and S. Palacios Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 22 2011 567 576
27. G.D. Lowe Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease J Intern Med 256 2004 361 374
28. J.H. Pickar, R. Lobo, B. Ebede, J. Thompson, and S. Mirkin Pooled cardiovascular safety results from phase 3 trials of bazedoxifene/conjugated estrogens Abstract from: the Annual Meeting of the North American Menopause Society October 3-6, Kissimmee, FL 2012
29. T.B. Clarkson, K.F. Ethun, N.M. Pajewski, D. Golden, E. Floyd, and S.E. Appt Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys Menopause 21 2014 8 14
30. G.D. Constantine, S. Mirkin, R.J. Cheng, K. Pan, and J.H. Pickar The effect of bazedoxifene with conjugated estrogens on body weight in postmenopausal women Poster presented at: the Annual Meeting of the North American Menopause Society September 30-October 3, San Diego, CA 2009
31. S.S. Girdler, C. O'Briant, J. Steege, K. Grewen, and K.C. Light A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women J Womens Health Gend Based Med 8 1999 637 646
32. T. Nevatte, P.M. O'Brien, and T. Backstrom ISPMD consensus on the management of premenstrual disorders Arch Womens Ment Health 16 2013 279 291
33. I.F. Godsland, K. Gangar, and C. Walton Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy Metabolism 42 1993 846 853
34. C.K. Sites, G.D. L'Hommedieu, M.J. Toth, M. Brochu, B.C. Cooper, and P.A. Fairhurst The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial J Clin Endocrinol Metab 90 2005 2701 2707
35. G.A. Greendale, B.A. Reboussin, S. Slone, C. Wasilauskas, M.C. Pike, and G. Ursin Postmenopausal hormone therapy and change in mammographic density J Natl Cancer Inst 95 2003 30 37
36. N.F. Boyd, G.A. Lockwood, J.W. Byng, D.L. Tritchler, and M.J. Yaffe Mammographic densities and breast cancer risk Cancer Epidemiol Biomarkers Prev 7 1998 1133 1144